SPOCD1: A Potential Drug Target and Biomarker (G90853)

Target Name: SPOCD1

NCBI ID: G90853

SPOCD1

SPOCD1: A Potential Drug Target and Biomarker

SPOCD1 (SPOC domain-containing protein 1, isoform 1) is a protein that has been identified as a potential drug target and biomarker. It is a member of the SPOC gene family, which encodes a family of proteins involved in various cellular processes, including cytoskeletal organization, cell signaling, and intracellular transport. SPOCD1 is unique among its family members due to its unique function and its ability to interact with small molecules, such as drugs.

SPOCD1 functions as a negative regulator of the cytoskeleton, which is responsible for the structure and function of the cell's cytoplasm. It helps maintain the integrity of the cytoskeleton by regulating the distribution of microtubules within the cell. In addition to its role in cytoskeletal organization, SPOCD1 has also been shown to play a role in cell signaling.

SPOCD1 has been shown to interact with a variety of small molecules, including drugs that are used to treat various diseases. For example, SPOCD1 has been shown to interact with the drug tasigna, which is used to treat diffuse large B-cell lymphoma. In addition, SPOCD1 has also been shown to interact with the drug axicabtagene ciloleucel (ACI), which is used to treat diffuse large B-cell lymphoma and other types of leukemia.

SPOCD1's ability to interact with small molecules makes it an attractive drug target. By targeting SPOCD1, researchers can potentially develop new treatments for various diseases. In addition, SPOCD1 may also be used as a biomarker to monitor the effectiveness of treatments. For example, the levels of SPOCD1 in the cytoplasm of cells treated with the drug tasigna could be used to assess the effectiveness of the treatment.

SPOCD1 is also a potential biomarker for tracking the progression of certain types of cancer. For example, SPOCD1 levels have been shown to be elevated in the cytoplasm of cells from patients with diffuse large B-cell lymphoma, a type of cancer that is characterized by the spread of large B-cell lymphocytes throughout the body.

In conclusion, SPOCD1 is a protein that has the potential to be a drug target and biomarker. Its unique function and ability to interact with small molecules make it an attractive target for researchers. Further studies are needed to fully understand the role of SPOCD1 in cellular processes and its potential as a drug target and biomarker.

Protein Name: SPOC Domain Containing 1

Functions: Essential excecutor of PIWIL4-piRNA pathway directed transposon DNA methylation and silencing in the male embryonic germ cells (By similarity). Associates with the de novo DNA methylation machinery and repressive chromatin remodeling complexes (By similarity). Tethering of PIWIL4 to a nascent transposable element transcript recruits repressive chromatin remodeling activities and the de novo methylation apparatus through SPOCD1 (By similarity). Not required for piRNA biosynthesis (By similarity)

The "SPOCD1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SPOCD1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets